The Priorix vaccine is indicated for active immunization to prevent measles, mumps and rubella.
Composition and form of release
Priorix is a lyophilizate for the preparation of a solution for injections. The drug contains inactivated measles, mumps and rubella viruses.
Priorix is used to prevent and reduce the incidence of measles, rubella and mumps through the formation of specific immunity in non-immunized infants of mothers who did not have rubella, children after one year of life, women who are susceptible to the rubella virus and planning to conceive. In addition, the drug can be used, if necessary, to immunize medical workers, students and military personnel.
Priorix is not prescribed if the patient during the examination revealed:
- primary or secondary immunodeficiency;
- acute viral diseases;
- exacerbation of chronic disease;
- hypersensitivity to the ingredients of the drug;
- an allergy to chicken eggs or neomycin.
Special caution should be taken when prescribing the drug if the patient has a history of convulsive syndrome and allergic reactions.
Application for pregnancy and lactation
Priorix is categorically contraindicated in pregnant women. If vaccination is necessary during lactation, the use of the drug is possible only after the balance of harm and benefit.
When vaccinating women of childbearing age, their consent is required to prevent pregnancy for three consecutive months after vaccination.
Method of application and dose
Priorix vaccine is administered subcutaneously or intramuscularly in a dosage of 0.5 ml.
When using the drug, remember that its intravenous administration is strictly prohibited!
The vaccine is administered in accordance with the vaccination schedule developed by the Ministry of Health.
At the moment, there have been no cases of overdose with Priorix, since the administration of the vaccine is strictly controlled by medical professionals.
It should be noted that Priorix vaccine is absolutely safe to use. The safety data are based on the fact that 12,000 people were injected with the drug in a clinical trial. After vaccination, the condition of the patients was monitored by medical workers for 42 days.
In the course of studies, patients after vaccination revealed: upper respiratory tract infections, rash, fever, in the injection area – pain, swelling and edema, otitis media, dyspeptic disorders, enlargement of the parotid glands, nervousness, insomnia, cough, conjunctivitis, allergic reactions …
Also, patients after vaccination may develop polyneuritis, myelitis, peripheral neuritis, encephalitis, erythema multiforme, arthralgia, arthritis, Kawasaki syndrome and anaphylactic reactions.
Storage conditions and periods
Priorix is stored in a dark place at a temperature of 2 to 8 degrees Celsius. The shelf life of the vaccine is 2 years.